Voluntary announcement - ascletis announces positive results from 28-day proof-of-concept clinical study in U.S. for asc50, a first-in-class and best-in-class oral small molecule il-17a inhibitor for the treatment of plaque psoriasis
Filed with HKEX · Stock code 1672 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Ascletis Pharma
- Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
- Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
- Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35